Publication Name	World Journal of Gastroenterology
Manuscript ID	80301
Country	United States

Received	2022-09-26 00:20
Peer-Review Started	2022-09-26 00:21
First Decision by Editorial Office Director	2022-10-18 07:41
Return for Revision	2022-10-18 07:41
Revised	2022-10-22 00:04
Publication Fee Transferred
Second Decision by Editor	2022-12-12 03:31
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2022-12-14 00:15
Articles in Press	2022-12-14 00:15
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-12-22 23:11
Publish the Manuscript Online	2023-01-04 05:53

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy
Manuscript Source	Invited Manuscript
All Author List	Seohyuk Lee and Saad Saffo
ORCID	Author(s) ORCID Number Seohyuk Lee http://orcid.org/0000-0003-3023-1304 Saad Saffo http://orcid.org/0000-0001-5375-3100
Funding Agency and Grant Number
Corresponding Author	Saad Saffo, MD, Academic Fellow, Department of Medicine, Section of Digestive Diseases, Yale School of Medicine, 333 Cedar Street, 1080 LMP, New Haven, CT 06520-8019, United States. saad.saffo@yale.edu
Key Words	Cirrhosis; Hepatic decompensation; Beta-blockers; Statins; Sodium-glucose cotransporter-2 inhibitors; Rifaximin
Core Tip	Hepatic decompensation is the most important clinical predictor of morbidity and mortality among patients with cirrhosis. New pharmacotherapies aimed at preventing hepatic decompensation in high-risk patients are emerging, augmenting traditional management strategies. These treatments represent safe, accessible, and effective options that may improve quality of life and prolong transplant-free survival, regardless of the etiologic factors involved.
Publish Date	2023-01-04 05:53
Citation	Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74
URL	https://www.wjgnet.com/1007-9327/full/v29/i1/61.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i1.61

Full Article (PDF)	WJG-29-61.pdf
Full Article (Word)	WJG-29-61.docx
Manuscript File	80301_Auto_Edited-LM.docx
Answering Reviewers	80301-Answering reviewers.pdf
Audio Core Tip	80301-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	80301-Conflict-of-interest statement.pdf
Copyright License Agreement	80301-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	80301-Language certificate.pdf
Peer-review Report	80301-Peer-review(s).pdf
Scientific Misconduct Check	80301-Bing-Wang JJ-2.png
Scientific Editor Work List	80301-Scientific editor work list.pdf
CrossCheck Report	80301-CrossCheck report.pdf